Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial is studying the side effects and best dose of eribulin mesylate and cisplatin in
treating patients with advanced solid tumors.Drugs used in chemotherapy, such as eribulin
mesylate and cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more tumor cells.